Valuence Merger Corp. I
Status: Pre-Deal
U=S+W/2
W=S@11.50
| IPO Proceeds, $M | $220.10M |
|---|---|
| IPO Date | Mar 1, 2022 |
| CEO | Sung Yoon Woo |
| Left Lead | SVB Securities |
| IPO Cash in Trust | 103.0% |
| SPAC Tenor | 15 + 12 + 21 |
| IPO Sector |
Healthcare
Developing breakthrough technology in life sciences and/or advancing a platform for sustainable technology in Asia (excluding China, Hong Kong and Macau) |
| IPO Geography | Asia |
| Target Company | TBD |
| Deal Announced | TBD |
| Deal Size, $M | TBD |
| Deal Sector | TBD |
| Deal Geography | TBD |
| SEC Filings | www.sec.gov |
| Approval Vote | TBD |
| Amendment Vote | Jun 3, 2024 |
VMCA
VMCAU
VMCAW
| Price | $11.51 |
|---|---|
| Last closing price | $11.51 |
| H/L, today | $11.51 / $11.51 |
| H/L, 52-week | $10.23 / $11.85 |
| Volume, today | 1,000 |
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on Valuence Merger Corp. I:
- Structure and cap table
- 9 directors & officers
- 29 filings and events
- 2 underwriters
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Sung Yoon Woo | 45 | CEO and Director |
| Sungwoo (Andrew)Hyung | 36 | CFO and Director |
| Sungsik (Sung) Lee | 45 | President |
| Dr. Gene Young Cho | 38 | COO |
| Dr. Joong Myung Cho | 72 | Director |
| John Kim | 54 | Director |
| Young Min Kim | 63 | Director |
| Gary Wunderlich | 51 | Director |
| Zhe Zhang | 47 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| SVB Securities | BR | 16,000,000 | units |
| Baird | 4,000,000 | ||
| 20,000,000 | units | ||
| Up-Front UW fee | 2.00 | % | |
| Deferred UW fee |
3.68 | % |
Sign in to view more advisor data.